ArticleCancer gene therapy2026
Potential for enhanced oncolytic HSV-1 therapy via SHED as a vehicle against malignant gliomas.
Article in Cancer gene therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Malignant gliomas are common primary brain tumors. Glioblastoma carries a poor prognosis, with median survival of less than 2 years. Given the urgent need for novel therapies, oncolytic virus (OV) therapy has developed rapidly. However, challenges remain with effective OV delivery to tumor sites and efficient infection of tumor cells. This study investigated the use of stem cells from human exfoliated deciduous teeth (SHED) as a potential vehicle for oncolytic herpes simplex virus-1 therapy (SHED-OV) to enhance treatment efficacy. SHED-OV showed a greater reduction in tumor cell viability in vitro than direct OV infection. Migration assays revealed that SHED-OV actively migrated toward glioma cell-conditioned medium, demonstrating their tumor-homing ability. In vivo experiments demonstrated significantly prolonged survival in both the glioma cell/SHED-OV co-implantation group and the OV-infected glioma cell group compared with controls. In a glioma stem cell model, both SHED-OV and OV alone significantly improved survival compared with controls, with SHED-OV achieving anti-tumor effects comparable to those of direct OV administration and complete tumor regression in a subset of mice. SHED-OV also exhibited tumor-homing ability. These results suggest that SHED could serve as an effective vehicle for OV delivery, potentially improving tumor infection and therapeutic efficacy.
Identifiers
42601389What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.